LAMIVUDINE; ZIDOVUDINE | A077558 | AUROBINDO PHARMA LTD
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Lupin Limited (Rakoczy Molino Mazzochi Siwik, LLP) - Citizen Petition FDA-2010-P-0549 · 5 docket documents Lupin Limited, represented by Rakoczy Molino Mazzochi Siwik LLP, filed this citizen petition on October 18, 2010, requesting that FDA confirm Teva Pharmaceuticals USA Inc. is not entitled to 180-day generic exclusivity under 21 U.S.C. § 355(j)(5)(B)(iv) for lamivudine and zidovudine tablets 150 mg/3 | 505(q) | 2010-10-26 | Denied | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.6918
per ea
Lowest NADAC/Unit
$0.6918
per ea
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 65862003660LAMIVUDINE-ZIDOVUDINE TABLET | $0.6918 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.